Dementia with Lewy bodies

Ian McKeith; Jacobo Mintzer; Dag Aarsland; David Burn; Helen Chiu; Jiska Cohen-Mansfield; Dennis Dickson; Bruno Dubois; John E. Duda; Howard Feldman; Serge Gauthier; Glenda Halliday; Brian Lawlor; Carol Lippa; Oscar L. Lopez; João Carlos MacHado; John O'Brien; Jeremy Playfer; Wayne Reid

doi:10.1016/S1474-4422(03)00619-7

Dementia with Lewy bodies

Ian McKeith, Jacobo Mintzer, Dag Aarsland, David Burn, Helen Chiu, Jiska Cohen-Mansfield, Dennis Dickson, Bruno Dubois, John E. Duda, Howard Feldman, Serge Gauthier, Glenda Halliday, Brian Lawlor, Carol Lippa, Oscar L. Lopez, João Carlos MacHado, John O'Brien, Jeremy Playfer, Wayne Reid

Neuroscience

Research output: Contribution to journal › Review article › peer-review

590 Scopus citations

Abstract

Dementia with Lewy bodies (DLB) is the second commonest cause of neurodegenerative dementia in older people. It is part of the range of clinical presentations that share a neuritic pathology based on abnormal aggregation of the synaptic protein α-synuclein. DLB has many of the clinical and pathological characteristics of the dementia that occurs during the course of Parkinson's disease. Here we review the current state of scientific knowledge on DLB. Accurate identification of patients is important because they have specific symptoms, impairments, and functional disabilities that differ from those of other common types of dementia. Severe neuroleptic sensitivity reactions are associated with significantly increased morbidity and mortality. Treatment with cholinesterase inhibitors is well tolerated by most patients and substantially improves cognitive and neuropsychiatric symptoms. Clear guidance on the management of DLB is urgently needed. Virtually unrecognised 20 years ago, DLB could within this decade be one of the most treatable neurodegenerative disorders of late life.

Original language	English (US)
Pages (from-to)	19-28
Number of pages	10
Journal	Lancet Neurology
Volume	3
Issue number	1
DOIs	https://doi.org/10.1016/S1474-4422(03)00619-7
State	Published - Jan 1 2004

ASJC Scopus subject areas

Clinical Neurology

Access to Document

10.1016/S1474-4422(03)00619-7

Cite this

@article{7eacd52c336d4e208ce98e9c4c182774,

title = "Dementia with Lewy bodies",

abstract = "Dementia with Lewy bodies (DLB) is the second commonest cause of neurodegenerative dementia in older people. It is part of the range of clinical presentations that share a neuritic pathology based on abnormal aggregation of the synaptic protein α-synuclein. DLB has many of the clinical and pathological characteristics of the dementia that occurs during the course of Parkinson's disease. Here we review the current state of scientific knowledge on DLB. Accurate identification of patients is important because they have specific symptoms, impairments, and functional disabilities that differ from those of other common types of dementia. Severe neuroleptic sensitivity reactions are associated with significantly increased morbidity and mortality. Treatment with cholinesterase inhibitors is well tolerated by most patients and substantially improves cognitive and neuropsychiatric symptoms. Clear guidance on the management of DLB is urgently needed. Virtually unrecognised 20 years ago, DLB could within this decade be one of the most treatable neurodegenerative disorders of late life.",

author = "Ian McKeith and Jacobo Mintzer and Dag Aarsland and David Burn and Helen Chiu and Jiska Cohen-Mansfield and Dennis Dickson and Bruno Dubois and Duda, {John E.} and Howard Feldman and Serge Gauthier and Glenda Halliday and Brian Lawlor and Carol Lippa and Lopez, {Oscar L.} and {Carlos MacHado}, Jo{\~a}o and John O'Brien and Jeremy Playfer and Wayne Reid",

note = "Funding Information: This review was the result of an IPA meeting held in Budapest in November 2002. The programme was organised and faculty invited by IPA. The meeting was funded with unrestricted educational grants from Janssen Pharmaceutical Products, LP, Johnson & Johnson Pharmaceutical Services, LLC, Targacept, Inc, AstraZeneca, and Forest Laboratories, Inc. All programming decisions and the resulting review were developed by IPA with no sponsor involvement. ",

year = "2004",

month = jan,

day = "1",

doi = "10.1016/S1474-4422(03)00619-7",

language = "English (US)",

volume = "3",

pages = "19--28",

journal = "Lancet Neurology",

issn = "1474-4422",

publisher = "Lancet Publishing Group",

number = "1",

}

TY - JOUR

T1 - Dementia with Lewy bodies

AU - McKeith, Ian

AU - Mintzer, Jacobo

AU - Aarsland, Dag

AU - Burn, David

AU - Chiu, Helen

AU - Cohen-Mansfield, Jiska

AU - Dickson, Dennis

AU - Dubois, Bruno

AU - Duda, John E.

AU - Feldman, Howard

AU - Gauthier, Serge

AU - Halliday, Glenda

AU - Lawlor, Brian

AU - Lippa, Carol

AU - Lopez, Oscar L.

AU - Carlos MacHado, João

AU - O'Brien, John

AU - Playfer, Jeremy

AU - Reid, Wayne

N1 - Funding Information: This review was the result of an IPA meeting held in Budapest in November 2002. The programme was organised and faculty invited by IPA. The meeting was funded with unrestricted educational grants from Janssen Pharmaceutical Products, LP, Johnson & Johnson Pharmaceutical Services, LLC, Targacept, Inc, AstraZeneca, and Forest Laboratories, Inc. All programming decisions and the resulting review were developed by IPA with no sponsor involvement.

PY - 2004/1/1

Y1 - 2004/1/1

N2 - Dementia with Lewy bodies (DLB) is the second commonest cause of neurodegenerative dementia in older people. It is part of the range of clinical presentations that share a neuritic pathology based on abnormal aggregation of the synaptic protein α-synuclein. DLB has many of the clinical and pathological characteristics of the dementia that occurs during the course of Parkinson's disease. Here we review the current state of scientific knowledge on DLB. Accurate identification of patients is important because they have specific symptoms, impairments, and functional disabilities that differ from those of other common types of dementia. Severe neuroleptic sensitivity reactions are associated with significantly increased morbidity and mortality. Treatment with cholinesterase inhibitors is well tolerated by most patients and substantially improves cognitive and neuropsychiatric symptoms. Clear guidance on the management of DLB is urgently needed. Virtually unrecognised 20 years ago, DLB could within this decade be one of the most treatable neurodegenerative disorders of late life.

AB - Dementia with Lewy bodies (DLB) is the second commonest cause of neurodegenerative dementia in older people. It is part of the range of clinical presentations that share a neuritic pathology based on abnormal aggregation of the synaptic protein α-synuclein. DLB has many of the clinical and pathological characteristics of the dementia that occurs during the course of Parkinson's disease. Here we review the current state of scientific knowledge on DLB. Accurate identification of patients is important because they have specific symptoms, impairments, and functional disabilities that differ from those of other common types of dementia. Severe neuroleptic sensitivity reactions are associated with significantly increased morbidity and mortality. Treatment with cholinesterase inhibitors is well tolerated by most patients and substantially improves cognitive and neuropsychiatric symptoms. Clear guidance on the management of DLB is urgently needed. Virtually unrecognised 20 years ago, DLB could within this decade be one of the most treatable neurodegenerative disorders of late life.

UR - http://www.scopus.com/inward/record.url?scp=9144224226&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=9144224226&partnerID=8YFLogxK

U2 - 10.1016/S1474-4422(03)00619-7

DO - 10.1016/S1474-4422(03)00619-7

M3 - Review article

C2 - 14693108

AN - SCOPUS:9144224226

SN - 1474-4422

VL - 3

SP - 19

EP - 28

JO - Lancet Neurology

JF - Lancet Neurology

IS - 1

ER -

Dementia with Lewy bodies

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this